Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q1 FY26 Earnings Presentation
22 slides from Alembic Pharmaceuticals's earnings presentation, Aug 5, 2025
Slide 1: Cover letter to stock exchanges
Date: 5th August, 2025 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 533573
Slide 2: Alembic Pharmaceuticals Limited Investor Presentation Q1 FY26
Alembic Pharmaceuticals Limited Investor Presentation Q1 FY26
Slide 3: Safe Harbour Statement
Safe Harbour Statement The materials and information presented herein may include forward looking statements , which reflect current expectations, projections, and assumptions. These statements are inherently subject to risks and uncertainties that could cause actual results or outcomes to differ ma
Slide 4: Quarterly Snapshot
Quarterly Snapshot Key Highlights Revenue INR 17.11 Bn India Branded Business +10% YoY Achieved an 5% YoY growth, with quarterly revenues of INR 5.99 billion US Generics EBIDTA INR 2.88 Bn Reported a 13% YoY increase, driven by the ramp up of key product launches +20% YoY EBIDTA Margin ~17% and mark
Slide 5: Revenue Summary
Revenue Summary INR Bn Business Q1 FY26 Q1 FY25 Y-o-Y Q4 FY25 Q-o-Q Formulations India Branded Business 5.99 5.72 5% 5.45 10% US Generics 5.23 4.61 13% 5.08 3% Ex-US Generics 3.28 2.71 21% 3.75 -13% API 2.61 2.59 1% 3.42 -24% Total Revenue 17.11 15.62 9.5% 17.70 -3% Q1 FY26 India Branded Business 15
Slide 6: India Branded Business – Performance
India Branded Business – Performance Revenue Q1 FY26 Revenue – last 5 Years CAGR: 12% INR Bn 23.39 22.00 Billions 20.63 19.26 17% 19% 14.96 23% Animal Health 23% Acute 60% 58% Specialty Q1FY25 Q1FY26 FY21 FY22 FY23 FY24 FY25 Sales Mix Q1 FY26 > The India Branded Business recorded 5% growth with reve
Slide 7: India Branded Business – Rx driven rankings
India Branded Business – Rx driven rankings Top Brands with Rank and Market Share Driving overall Prescription business BRANDS Rank MS% Q1 BRANDS Rank MS% 129 131 Q1 FY 26* Q1 Q1 FY 26* FY 26* FY 26* 0.24 0.23 AZITHRAL 1 34.1 BROZEET-LS 3 6.5 ALTHROCIN 1 88.5 CLOFF 3 11.9 CRINA-NCR 1 28.9 BLADMIR 3
Slide 8: Animal Health Business
Animal Health Business Revenue Q1 FY26 Growth: 17% INR Mn Revenue – last 5 Years CAGR: 24% INR Mn Billions 1143 4305 3553 2860 2320 976 1841 Q1FY25 Q1FY26 FY21 FY22 FY23 FY24 FY25 Sales Mix Q1 FY26 > Alembic operates in the Livestock, Poultry, and Companion Animal Antibiotic segments. > Market leade
Slide 9: Strategic tech initiatives enhancing competitiveness, productivity & insights
Strategic tech initiatives enhancing competitiveness, productivity & insights 01 Introduced iPad-based engagement for field force to enhance brand communication with healthcare professionals 02 Migrated to Salesforce CRM for seamless field operations, ensuring a 360-degree view of HMPs in real time
Slide 10: US Generics Business
US Generics Business Revenue Q1 FY26 Growth: 13% INR Bn Revenue – last 5 Years INR Bn 21.63 19.57 17.30 5.23 16.66 15.72 4.61 Q1FY25 Q1FY26 FY21 FY22 FY23 FY24 FY25 Approved ANDAs > Well established US front end with strong customer base. Total 223* * Includes 23 Tentative Approval > 4 products laun
Slide 11: Ex US Generics Business
Ex US Generics Business Revenue Q1 FY26 Growth: 21% INR Bn Revenue – last 5 Years CAGR: 12% INR Bn 12.43 3.28 10.52 2.71 8.52 7.75 Q1FY25 Q1FY26 7.79 > Achieved 21% YoY growth in Q1, driven by higher offtake and an optimized product mix. > Key partnerships active in Europe, Canada, Australia, Brazil
Slide 12: API Business
API Business Revenue Q1 FY26 Revenue – last 5 Years Growth: 1% INR Bn CAGR: 4% INR Bn 12.46 11.66 11.33 2.59 2.61 9.55 9.39 Q1FY25 Q1FY26 > Reported 1% YoY growth, led by increased volume offset by pricing pressures. > Cumulative DMF filings with US FDA stands at 140. > Continued focus on cost effic
Slide 13: R&D and R&D Capabilities
R&D Dosage form wise ANDA Fillings, Approval and Launch in Q1FY26 Continued investment in building product pipeline INR Bn Q1 FY26 Filings 4 Q1 FY26 Approval 4 15.8% 3 Q1 FY26 Launch 14.0% 3 12.8% 2 7.8% 1 1 7.6% R&D Spend 1 1 1 1 8.4 R&D % of sales 6.7 7.2 4.8 5.2 0 OSD OSD - Onco Injectables Injec
Slide 14: Q1-FY26 Financials Summary
Q1-FY26 Financials Summary INR Bn Particulars Q-1 FY25 Q-4 FY25 Q-1 FY26 YoY(%) QoQ(%) Revenue from Operations 15.62 17.70 17.11 10% -3% Other Income 0.02 0.14 0.07 Total Income 15.64 17.84 17.17 10% -4% Material Consumption 3.94 5.31 4.07 3% -23% Employee benefits expense 3.80 3.94 4.23 11% 7% Othe
Slide 15: Company Overview
Company Overview Alembic Pharmaceuticals Ltd. Investor Presentation Q1 FY26
Slide 16: Company at a Glance
Company at a Glance Mission Team Size ANDA Filings R&D Centers Manufacturing Facilities Improve Healthcare with 16,500+ 268 (Jun 30,2025) 2 10 innovation, commitment and Trust Prescribers in India Field Force Brands Net Zero Target Products in US ~2,40,000 5,500+ 205 2050 167 Alembic Pharmaceuticals
Slide 17: Value Proposition
Value Proposition Developing specialty drug pipeline Supplying APIs to 60+ countries for India globally Established presence in Chile & Exploring opportunities in UAE Injectables Ranks 21th in the Indian Expanding product portfolio in US formulations market Consistent, High Dividend Payout Strengthe
Slide 18: The Journey
The Journey 2012 Formed a JV, Rhizen , for 2025 2006 Indore facility NCE Research FDA Commissioned 2007 & approved API facility Acquired Acquired Utility Dabur’s Indian Therapeutics Cardiology, GI & 2013 Limited 1907 Gynecology 2010 Launched first 2013 2023 brands NDA with a Established by Pharmaceu
Slide 19: Robust infrastructure
Robust infrastructure Dosage Form Last USFDA Audit International Generics F1 - Panelav General Oral Solids July’24 F2 - Panelav Oncology Oral Solids Mar’24 Oncology Injectables Oct’24 F3 - Karkhadi General Injectables Mar’23 Ophthalmic F2 - Panelav F3 - Karkhadi F4 - Jarod General Oral Solids Nov’24
Slide 20: Yearly Financials
Yearly Financials INR Bn Revenue EBIDTA Net Profit 6.65 10.53 10.53 6.16 66.72 9.61 # 5.84 62.29 56.53 4.97 # 53.06 7.79 # FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 EBIDTA margin % Capex ROCE % 20% 5.75 25% * 16% 4.67 14% # 15% # 4.12 3.45 15% *# 16%*# 14%*# FY22 FY23 FY24 FY25 FY2
Slide 21: Sustainability: Alembic's ESG Targets
Sustainability Alembic’s ESG Targets Net Zero by 2050 • 63% GHG Emission reduction by 2034 Water Neutrality by 2027 50,000 trees by 2027 • 90% GHG Emission reduction by 2050 (Approved by SBTi) Environment Social Governance • One of the 10 Indian Pharma companies • Zero fatality • Implemented supplie
Slide 22: Thank You
Thank You For further queries, please contact: Investor Relations Advisors Mr. Ajay Desai Adfactors PR Pvt. Ltd. ajay.desai@alembic.co.in 022-6695 3681 Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactorspr.com 2nd Floor, Prime Corporate Park Sahar Road, Andheri Ea
Alembic Pharmaceuticals — Q1 FY26 Earnings Presentation on 6ix